Biohit OyjLTS:0DRP +0.20%78 Market Cap is €37.56 Mil as of Jun. 29, 2026. GuruFocus rates LTS:0DRP with a GF Score™ of 78/100 and a GF Value™ of €2.76 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 867 Medical Devices & Instruments companies, Biohit Oyj ranks worse than 64.13% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Biohit Oyj's share price for the quarter that ended in Dec. 2025 was €3.6. Biohit Oyj's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 15.20 Mil. Therefore, Biohit Oyj's market cap for the quarter that ended in Dec. 2025 was €54.71 Mil.
Biohit Oyj's quarterly market cap
increased
from Dec. 2024 (€35.37 Mil) to Jun. 2025 (€41.91 Mil) and
increased
from Jun. 2025 (€41.91 Mil) to Dec. 2025 (€54.71 Mil).
Biohit Oyj's annual market cap
declined
from Dec. 2023 (€75.65 Mil) to Dec. 2024 (€35.37 Mil) but then
increased
from Dec. 2024 (€35.37 Mil) to Dec. 2025 (€54.71 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Biohit Oyj's Enterprise Value for Today is €34.30 Mil.
Biohit Oyj (LTS:0DRP) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Biohit Oyj Market Cap Related Terms
Biohit Oyj Market Cap Historical Data
* Premium members only.
The historical data trend for Biohit Oyj's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Biohit Oyj's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's Market Cap distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Biohit Oyj's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohit Oyj (LTS:0DRP) has a Market Cap of €37.56 Mil as of Jun. 29, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Biohit Oyj and its competitors. According to the industry distribution chart, Biohit Oyj ranks #556 out of 867 companies in the Medical Devices & Instruments industry, placing it in the top 64.1%.
Is Biohit Oyj's Market Cap too high?
Biohit Oyj's current Market Cap is €37.56 Mil. Based on the distribution chart, Biohit Oyj ranks #556 out of 867 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Biohit Oyj has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #556 out of 867 companies for Market Cap. This places Biohit Oyj in the lower half of its industry. The industry median Market Cap is 117.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 117.03, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Biohit Oyj and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 117.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biohit Oyj's current Market Cap is €37.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.76, compared to a current price of €2.47 — trading 10.5% below its estimated fair value. The current Market Cap is €37.56 Mil. Biohit Oyj's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current Market Cap is €37.56 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be undervalued.
The current stock price of €2.47 is trading 10.5% below its estimated GF Value™ of €2.76.
GuruFocus considers Biohit Oyj to be Modestly Undervalued.
Key valuation signals for LTS:0DRP:
Market Cap: €37.56 Mil
GF Value™: €2.76 vs. price of €2.47 (10.5% below fair value)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score
Get the complete analysis for LTS:0DRP
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
